The Clinical Role of Inflammatory Chemokine RANTES (CCL5) in a Sample of COVID-19 Baghdad Province Patients

COVID-19 disease is a clinical syndrome caused by an envelope RNA virus, called SARS-COV-2., which causes infection with wildly clinical pictures. Through COVID-19 infection several components of humoral and cellular immune response have an important role in the progression of the infection. Chemokines are one of the inflammatory mediators that play an essential role in the immune pathogenesis of COVID-19. It is secreted by respiratory virus-infected cells in the upper respiratory tract, causing stimulation and recruitment of inflammatory cells such as neutrophils, NK, eosinophils, and macrophages from the bloodstream to the site of the infection. This study strives to determine the impact role of inflammatory mediator chemokine RANTES (CCL5) in COVID-19 Iraq patients. Blood samples collected from 180 individuals were enrolled in this study, 120 of them were patients infected with COVID-19 and verified by reverse transcriptase polymerase chain reaction (RT-PCR). The patients were categorized into two groups based on the severity of the disease, the severe group included 60 patients and the mild/moderate group included 60 patients also. Furthermore, 60 healthy individuals who were confirmed to be COVID-19-negative were enrolled in this study as a control group. The quantitative detection of CCL5 in human serum was done by the CCL5 Enzyme Linked Immune Sorbent Assay kit based on the principle of sandwich ELISA. This study showed that there were interesting highly significant differences (p<0.001) in the median serum level of CCL5 between all groups that participated in this study and there was a significant increase in the median level of CCL5 in control and mild-moderate groups versus severe patients’ group (66.66 pg/ml, and 54.04 pg/ml vs. 38.41 pg/ml respectively). According to the results of this study, the low level of CCL5 associated with COVID-19 severity infection could be used as a predictor marker for severity while the elevated level of CCL5 in control and mild-moderate suggested the elevated level of this chemokine is likely to be associated with the resolution of inflammation and recovery.

Authors

Institutions

Publication Details

Journal
Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
Published
2025-02-15
DOI
https://doi.org/10.31351/vol33iss(4si)pp304-311
Citations
1
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Clinical Role of Inflammatory Chemokine RANTES (CCL5) in a Sample of COVID-19 Baghdad Province Patients

Ghaith Hamid Hameed, Zahra'a Abdul AL-Aziz Yousif, Jabbar S. Hassan
1 citations
Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
COVID-19 Clinical Research Studies
1.40
article

The Clinical Role of Inflammatory Chemokine RANTES (CCL5) in a Sample of COVID-19 Baghdad Province Patients

Ghaith Hamid Hameed, Zahra'a Abdul AL-Aziz Yousif, Jabbar S. Hassan
article en
1 citations

Abstract

COVID-19 disease is a clinical syndrome caused by an envelope RNA virus, called SARS-COV-2., which causes infection with wildly clinical pictures. Through COVID-19 infection several components of humoral and cellular immune response have an important role in the progression of the infection. Chemokines are one of the inflammatory mediators that play an essential role in the immune pathogenesis of COVID-19. It is secreted by respiratory virus-infected cells in the upper respiratory tract, causing stimulation and recruitment of inflammatory cells such as neutrophils, NK, eosinophils, and macrophages from the bloodstream to the site of the infection. This study strives to determine the impact role of inflammatory mediator chemokine RANTES (CCL5) in COVID-19 Iraq patients. Blood samples collected from 180 individuals were enrolled in this study, 120 of them were patients infected with COVID-19 and verified by reverse transcriptase polymerase chain reaction (RT-PCR). The patients were categorized into two groups based on the severity of the disease, the severe group included 60 patients and the mild/moderate group included 60 patients also. Furthermore, 60 healthy individuals who were confirmed to be COVID-19-negative were enrolled in this study as a control group. The quantitative detection of CCL5 in human serum was done by the CCL5 Enzyme Linked Immune Sorbent Assay kit based on the principle of sandwich ELISA. This study showed that there were interesting highly significant differences (p<0.001) in the median serum level of CCL5 between all groups that participated in this study and there was a significant increase in the median level of CCL5 in control and mild-moderate groups versus severe patients’ group (66.66 pg/ml, and 54.04 pg/ml vs. 38.41 pg/ml respectively). According to the results of this study, the low level of CCL5 associated with COVID-19 severity infection could be used as a predictor marker for severity while the elevated level of CCL5 in control and mild-moderate suggested the elevated level of this chemokine is likely to be associated with the resolution of inflammation and recovery.

Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)Vol. 33((4SI))
Baghdad Medical City (IQ), Nahrain University (IQ)
Openalex Percentile: Top 24%
COVID-19 Clinical Research Studies
1.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.